Qiagen NV 

$48.57
59
+$0.25+0.52% Friday 21:00

Statistics

Day High
48.72
Day Low
47.96
52W High
57.82
52W Low
37.63
Volume
1,354,908
Avg. Volume
2,091,016
Mkt Cap
0
P/E Ratio
27.72
Dividend Yield
0.54%
Dividend
0.26

Upcoming

Dividends

0.54%Dividend Yield
Jan 26
$2.41
Jul 25
$0.26
Jul 25
$0.26
Jan 25
$1.33
Jan 24
$1.35
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-49.99%

Earnings

4MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.5
0.55
0.6
0.64
Expected EPS
0.541943
Actual EPS
N/A

Financials

19.93%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
6.75BRevenue
1.34BNet Income

Analyst Ratings

$54.80Average Price Target
The highest estimate is 60.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
40%
Hold
60%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QGEN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Qiagen's sample and assay technologies.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a broad range of reagents, instruments, and consumables used in biological and medical research, competing with Qiagen in multiple areas including sample preparation and diagnostics.
Bio-Rad Laboratories
BIO
Mkt Cap8.54B
Bio-Rad Laboratories offers products and systems used to separate complex chemical and biological materials, directly competing with Qiagen in the life sciences research market.
Agilent Technologies
A
Mkt Cap41.49B
Agilent Technologies provides instruments, services, consumables, applications, and expertise, focusing on the life sciences, diagnostics, and applied chemical markets, competing with Qiagen in diagnostics and research.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers sequencing systems that compete with Qiagen's genomic and DNA sequencing solutions.
Repligen
RGEN
Mkt Cap8.39B
Repligen Corporation provides bioprocessing technologies and systems that compete with Qiagen's solutions for the purification and isolation of biological samples and substances.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories, through its Class B shares, competes in the same space as its Class A shares, offering similar products and technologies that rival Qiagen's offerings.
Hologic
HOLX
Mkt Cap16.45B
Hologic specializes in diagnostics, medical imaging systems, and surgical products, competing with Qiagen in the diagnostics and women's health market.
Quest Diagnostics
DGX
Mkt Cap19.57B
Quest Diagnostics provides diagnostic testing, information, and services, competing with Qiagen in the diagnostics and molecular diagnostics markets.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing with Qiagen in the precision medicine and cancer diagnostics space.

About

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Show more...
CEO
Mr. Thierry Bernard
Employees
5700
Country
NL
ISIN
NL0015002SN0

Listings

0 Comments

Share your thoughts

FAQ

What is Qiagen NV stock price today?
The current price of QGEN is $48.57 USD — it has increased by +0.52% in the past 24 hours. Watch Qiagen NV stock price performance more closely on the chart.
What is Qiagen NV stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Qiagen NV stocks are traded under the ticker QGEN.
Is Qiagen NV stock price growing?
QGEN stock has fallen by -3.65% compared to the previous week, the month change is a -10.47% fall, over the last year Qiagen NV has showed a +16.61% increase.
When is the next Qiagen NV earnings date?
Qiagen NV is going to release the next earnings report on May 04, 2026.
What were Qiagen NV earnings last quarter?
QGEN earnings for the last quarter are 0.62 USD per share, whereas the estimation was 0.6 USD resulting in a +2.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Qiagen NV revenue for the last year?
Qiagen NV revenue for the last year amounts to 6.75B USD.
What is Qiagen NV net income for the last year?
QGEN net income for the last year is 1.34B USD.
Does Qiagen NV pay dividends?
Yes, QGEN dividends are paid annual. The last dividend per share was 2.41 USD. As of today, Dividend Yield (FWD)% is 0.54%.
How many employees does Qiagen NV have?
As of February 22, 2026, the company has 5,700 employees.
In which sector is Qiagen NV located?
Qiagen NV operates in the Health Care sector.
When did Qiagen NV complete a stock split?
The last stock split for Qiagen NV was on January 08, 2026 with a ratio of 19:20.
Where is Qiagen NV headquartered?
Qiagen NV is headquartered in Venlo, NL.